A Phase Ⅱ ,Open-label ,Single Institution Study to Investigate the Efficacy and Safety of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Camrelizumab (Primary) ; Doxorubicin (Primary) ; Ifosfamide (Primary)
- Indications Dermatofibrosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 04 Jun 2024 Results (n=35; to date) assessing efficacy and safety of camrelizumab combined with chemotherapy for high-risk Soft Tissue Sarcoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 22 Mar 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 22 Mar 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Oct 2020).